{"organizations": [], "uuid": "aa690afd0f5f869f9810b9baa7f2f7ebe8cabff2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-argos-therapeutics-reports-results/brief-argos-therapeutics-reports-results-of-interim-analysis-of-the-adapt-trial-and-announces-review-of-strategic-alternatives-idUSASC09WGZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Argos Therapeutics Reports Results Of Interim Analysis Of The Adapt Trial And Announces Review Of Strategic Alternatives", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T20:07:00.000+03:00", "replies_count": 0, "uuid": "aa690afd0f5f869f9810b9baa7f2f7ebe8cabff2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-argos-therapeutics-reports-results/brief-argos-therapeutics-reports-results-of-interim-analysis-of-the-adapt-trial-and-announces-review-of-strategic-alternatives-idUSASC09WGZ", "ord_in_thread": 0, "title": "BRIEF-Argos Therapeutics Reports Results Of Interim Analysis Of The Adapt Trial And Announces Review Of Strategic Alternatives", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "argos therapeutics inc", "sentiment": "negative"}, {"name": "brief-argos therapeutics reports results of interim", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "stifel", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Argos Therapeutics Inc:\n* ARGOS THERAPEUTICS REPORTS RESULTS OF INTERIM ANALYSIS OF THE ADAPT TRIAL AND ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES\n* ARGOS THERAPEUTICS INC - COMPANY TO TERMINATE ADAPT STUDY\n* ARGOS THERAPEUTICS INC - COMPANY HAS RETAINED STIFEL TO PROVIDE ADVICE ON POSSIBLE STRATEGIC ALTERNATIVES\n* ARGOS THERAPEUTICS INC - TRADING IN COMMON STOCK TO BE TRANSFERRED FROM NASDAQ TO OTCQB VENTURE MARKET\n* ARGOS THERAPEUTICS - STRATEGIC ALTERNATIVES MAY INCLUDE A POTENTIAL MERGER OR SALE OF CO\n* ARGOS - ESTIMATED MEDIAN OVERALL SURVIVAL FOR COMBO ARM WAS 28.2 MONTHS VERSUS 31.2 MONTHS FOR CONTROL ARM IN MOST RECENT ANALYSIS OF ADAPT TRIAL DATA\n* ARGOS - TWO OTHER CO-PRIMARY ENDPOINTS IN ADAPT TRIAL ALSO DID NOT DEMONSTRATE A FAVORABLE RESULT\n* ARGOS - FOURTH ENDPOINT, FIVE-YEAR SURVIVAL, WAS NOT EVALUATED IN ADAPT TRIAL AS THERE WAS INSUFFICIENT DATA Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T20:07:00.000+03:00", "crawled": "2018-04-20T12:03:26.013+03:00", "highlightTitle": ""}